Background: The Advisory Committee on Immunization Practices recommends routine childhood vaccination by age 2 years, yet evidence suggests that only 2% to 26% of children receive vaccine doses at age-appropriate times (compliance). The objective of this study was to estimate vaccine completion and compliance rates between birth and age 2 years using recent, nationally representative data. Methods: Using a sample of children aged 24 to 35 months from the 2012 National Immunization Survey (NIS), the present study examined completion and compliance of recommended childhood vaccines. A state-specific examination of vaccine completion and compliance was also conducted.
Introduction
The Advisory Committee on Immunization Practices (ACIP) recommends children receive multiple vaccinations between birth and age 2 years to protect against 14 diseases [1] . The recommended series includes completion of four doses of diphtheria, tetanus, and acellular pertussis vaccine (DTaP); three doses of inactivated poliovirus vaccine (IPV); one dose of measles, mumps, Abbreviations: ACIP, Advisory Committee on Immunization Practices; DTap, diphtheria, tetanus, and acellular pertussis vaccine; HepA, hepatitis A vaccine; HepB, hepatitis B vaccine; Hib, Haemophilus influenzae type b vaccine; IIS, immunization information systems; IPV, inactivated poliovirus; MMR, measles, mumps, and rubella vaccine; NIS, national immunization survey; PCV, pneumococcal conjugate vaccine; SCHIP, State Children's Health Insurance Program; US, United States.and rubella vaccine (MMR); three or four doses of Haemophilus influenzae type b vaccine (Hib); three doses of hepatitis B vaccine (HepB); one dose of varicella vaccine; and four doses of pneumococcal conjugate vaccine (PCV) (i.e., 4:3:1:3:3:1:4). Additionally, the ACIP recommends receipt of two or three doses of rotavirus vaccine, one or two doses of influenza vaccine; and at least one dose of hepatitis A vaccine (HepA) by age 2 years.
Evidence suggests that appropriate vaccination coverage is linked to improved health outcomes and cost savings [2, 3] . A decision-analytic model examining completion of the childhood vaccination schedule in a 2009 United States (US) birth cohort indicated prevention of approximately 42,000 early deaths and 20 million cases of disease in their lifetime. Moreover, the analyses showed that routine vaccination may lead to an offset of approximately $69 billion in total societal costs [3] . The Healthy People 2020 Immunization and Infectious Disease goals targets 90% of children to receive all doses of individual vaccines (i.e., DTaP, IPV, MMR, Hib, HepB, and varicella), 80% to receive all doses of rotavirus vaccine, and 80% to receive all doses in the 4:3:1:3:3:1:4 series by age 19 to 35 months [2] .
Although, vaccination coverage has improved in the US over recent years, data from the National Immunization Survey (NIS) found approximately 68% of 2-year-old children completed all doses in the 4:3:1:3:3:1:4 series in 2012. Furthermore, targets of 90% completion were not achieved for DTaP (83%), PCV (82%), and HepA (82%) vaccines. Similarly, receipt of rotavirus vaccine (69%) was below the target of 80% [4] .
Complying with age-appropriate receipt of vaccinations is critical for providing maximum effectiveness against vaccinepreventable diseases [1] . However, prior studies indicate that only 2% to 26% of 2-year-olds actually comply with the age recommendations for each vaccine dose [5, 6] . Although these studies provide novel information on vaccination rates, they were conducted approximately 10 years ago. As vaccination recommendations and coverage patterns have changed, recent assessments of vaccine compliance are needed.
In this study, we examined completion and compliance rates of childhood vaccinations among a nationally representative sample of children in the US. We assessed the proportion of children who received recommended doses of vaccine by age 2 years, the number of doses received at age-appropriate times, the cumulative number of days undervaccinated, and geographic variations of completion and compliance.
Methods

Data source: National Immunization Survey
Data for this study were derived from the 2012 NIS Public Use File [7, 8] . The NIS is an annual population-based survey conducted by the National Center for Immunization and Respiratory Diseases, the National Center for Health Statistics, and the Centers for Disease Control and Prevention. It consists of a list-assisted random digit-dialing landline and cellular telephone survey (household interview) to guardians of children aged 19 to 35 months to collect demographic and vaccination information. Immunization provider(s) reports the child's vaccination history. Data were weighted to represent the greater US population, adjusting for households with multiple telephone lines, no telephone service, and nonresponse. Detailed NIS methods and institutional review board approval for data analysis are reported elsewhere [9, 10] . RTI International's institutional review board determined that this study met all criteria for exemption (ID Number 13523).
Study sample
The 2012 NIS contains information on 25,736 (unweighted sample) children aged between 19 to 35 months. From this sample, we selected children who completed the survey, lived in the US (excluding the US Virgin Islands), and had adequate vaccination data supplied by their vaccine providers. Children aged less than 24 months at the time of the survey were excluded. This restriction allowed for an equal vaccine capture period for all included children (i.e., birth to 24 months). The final unweighted sample size was 11,710, equating to a weighted sample of 4,083,928 children.
Study measures
2.3.1. Vaccine completion ACIP recommendations [1] were used to define vaccine completion at specific time points (8, 18 , and 24 months of age). Vaccine completion was defined as the accumulation of the required number of doses by a specific age irrespective of timing of vaccine administration. For example, children receiving three doses of DTaP, two doses of IPV, two or three doses of Hib, two doses of HepB, and three doses of PCV vaccines by 8 months were considered to have completed the appropriate doses in the 4:3:1:3:3:1:4 vaccination series at that time. Rotavirus vaccine was also assessed at each time point. A detailed list of doses required at each time period is presented in Table 1 .
As the required number of doses of rotavirus and Hib vaccines are dependent on the product administered, we assessed completion accordingly. For example, a child's vaccination for rotavirus was considered complete if two doses of Rotarix TM (GSK Vaccines) or three doses of RotaTeq (Merck & Co., Inc.) were administered. These algorithms are detailed in the published vaccine schedule [1] .
Although the ACIP recommends two doses of influenza vaccine beginning at age 6 months and one dose of influenza vaccine annually thereafter, we have not included it in this study. Influenza vaccines should be administered prior to or during influenza season. As the NIS data only provide the child's age at which the vaccine was administered, we were unable to assess whether or not the vaccine was given during an influenza season, which prevented computation of accurate completion or compliance measures.
Two doses of HepA are recommended by age 2 years, with the first dose occurring after 12 months and the second dose occurring 6 to 18 months after the first dose. Given the second dose may be received outside of our observation period (birth to 24 months), we were unable to accurately compute completion and compliance of both doses. Therefore, HepA is not included in the present analysis. 
Vaccine compliance
The ACIP recommends vaccination at specific ages and intervals to provide maximum effectiveness and to ease scheduling through matching the well-child visit schedule [1] . Therefore, we calculated vaccine compliance as the proportion of children who received each dose during the ACIP's recommended age-appropriate windows (e.g., dose 1 of DTaP at 2 months) ( Table 2 ). The ACIP allows early vaccination as "age-appropriate" if received within a 4-day grace period prior to the minimum age for the dose [13] . Therefore, any vaccines administered during this grace period were included as on time, and any vaccines administered before this grace period were excluded from calculation of the compliance endpoint.
We assessed the number of days a child was undervaccinated using the method proposed in several prior vaccine compliance studies [5, 11] . A day undervaccinated was defined as a day where the child had not completed the age-appropriate doses recommended by that day. This was assessed by summing the total number of days a delayed vaccine was given after the recommended age range, per child. Each day of undervaccination was counted as 1 day, regardless of the number of vaccines missed by that day [12] . If a dose was never received by 24 months, the child received the maximum number of days undervaccinated based on the total number of days between the first day of undervaccination and age 24 months. The final measure of vaccine compliance was the total number of days undervaccinated. Accumulation of 7 months or more of undervaccination was categorized as "severely undervaccinated". In addition to reporting total compliance of each dose and series, we also assessed all doses received on time, some doses received on time, and no doses received on time.
Statistical analyses
Estimates of frequencies, percentages, means, standard errors, and medians were calculated using SAS statistical software, version 9.3 (SAS Institute, Inc., 2011). Survey procedures and domain analysis techniques were used to calculate weighted values and standard errors. To understand geographic trends of completion and compliance, we mapped key measures by state using SAS map procedures.
Results
Study sample characteristics are presented in Table 3 . Of the mothers of the sampled children, 57% were aged 30 years or older, 63% were married, 38% resided in the South, and 55% were educated beyond high school. Approximately 51% of children were male, 47% were non-Hispanic White, and 75% had siblings in the household. The majority of providers were based in private practice (58%) and had one vaccine provider (66%). About half of children were enrolled in Medicaid or the State Children's Health Insurance Program (SCHIP). DTaP (80%), Hib (79%), HepB (89%), PCV (80%), and rotavirus (68%) were below the target. Drops in completion rates were observed for the majority of vaccines between the 8-month and 18-month time points. This reduction ranged from 1% (IPV) to 13% (DTaP). Completion rates rose again by 24 months and were similar to those observed at 8 months.
Vaccine completion
Vaccine compliance
Vaccine compliance varied by type of vaccine (Table 5 ). Rates ranged from 41% of children receiving all doses of Hib at age-appropriate times to 78% receiving a dose of MMR at ageappropriate times. Among multi-dose vaccines, rotavirus (22%) had the greatest proportion of children with all doses late, followed by PCV (12%), Hib (11%), DTaP (9%), and IPV (7%). More than half of children had at least one late dose in the Hib and PCV series, whereas less than one-quarter of children had a late dose of IPV (24%), MMR (22%), and varicella (22%)
Total days undervaccinated and severe undervaccination varied by vaccine. The mean number of days undervaccinated was lowest for MMR (152 days) and varicella (154 days), and highest for rotavirus (475 days) and PCV (258 days). Severe undervaccination occurred more frequently for rotavirus than for any other vaccine, with 33% of children severely undervaccinated and 42% of children with at least one late dose. Approximately one-quarter of children were severely undervaccinated with PCV (26%) and Hib (28%). IPV (9%), MMR (11%), varicella (11%), HepB (13%), and DTaP (15%) had the lowest proportion of children with severe undervaccination. Undervaccination of doses in the 4:3:1:3:3:1 and 4:3:1:3:3:1:4 series was, on average, 261 and 282 days, respectively, and 39% and 43% of children were severely undervaccinated, respectively. Table 1 ). For the 4:3:1:3:3:1:4 series, the highest completion rates were observed for the Southern states (i.e., Mississippi, Tennessee, Virginia, North Carolina, South Carolina, and Georgia) and some Midwest states (i.e., North Dakota, Nebraska, Iowa, and Wisconsin), with Mississippi having the highest completion rate (77%). Western states (i.e., California, Oregon, Nevada, and Alaska) were among the states with the lowest completion rates. Vaccine completion was lowest in Alaska (55%). Vaccine compliance showed little variation, with the many states in the South, Midwest, and Southwest falling in the 20% to 29% compliance range. Compliance rates were low in some Western states (i.e., California, Oregon, Nevada, and Alaska). Colorado (39%) had the highest compliance rate, while Alaska (2%) had the lowest. The majority of states had severe undervaccination rates over 40%. Severe undervaccination was highest in Alaska (80%) and lowest in New Hampshire (28%).
State-specific completion and compliance
Fig. 1 depicts vaccination completion and compliance rates in the US (detailed in Supplemental
Discussion
Completion rates of several childhood vaccines have met Healthy People 2020 thresholds over the past several years [4] . Consistent with those estimates, we found overall completion rates IPV, MMR, HepB, and varicella were approximately 90%. However, the proportion of children receiving all vaccines in the 4:3:1:3:3:1:4 series was low (66%).
Findings from this analysis revealed that for most of the vaccines, completion rates dropped between age 8 and 18 months, then increased by 24 months. This trend is consistent with Robison and colleagues [14] , who found that between 11% and 21% of children whose vaccination is complete at an interim milestone will have incomplete vaccinations by the next milestone. This suggests the current benchmarking method of assessing completion at 2 years of age masks the true dynamic nature of immunization status between birth and age 2 years. It is plausible that children who are considered up-to-date at 2 years of age (or earlier measurement points) may have received vaccines too early or too late prior to the measurement point, thus leaving them vulnerable to vaccine-preventable diseases at earlier times. In a study of pediatric pertussis cases over a 6-year period, researchers found that less than half had received the DTaP immunization at age-appropriate times [15] , underlining the importance of age-appropriate vaccinations for timely protection. Measuring vaccine compliance allows us to evaluate levels of protection throughout the first 2 years, a time during which children are most susceptible to severe complications related to vaccine-preventable diseases. Vaccine compliance has been examined in several studies with varying methods [5] [6] [7] 16, 17] . Luman and colleagues [11] found only 9% of 19-to 35-month-old children received all vaccines in the 4:3:1:3:3:1 series within the appropriate age ranges. Our current study found that compliance for both 4:3:1:3:3:1 (26%) and 4:3:1:3:3:1:4 series (23%) was substantially higher. Better compliance rates could be attributed to an improvement in immunization strategies over the past 15 years. Nonetheless, nearly 75% of children do not receive all doses on time, providing further support that a large proportion of children are not adequately immunized between birth and 24 months. We also found that a high proportion of children were severely undervaccinated, which may point to issues with accessing preventative care, vaccine delivery, or intentional refusal to complete the series [5] .
In the state-specific analysis, observed regional trends may indicate geographic differences in the factors impacting vaccination behavior and uptake. For example, Western states such as Oregon, California, Nevada, and Alaska had low completion and low compliance rates, indicating that children were not receiving vaccines at all or on time. This trend may be reflective of the high prevalence of vaccine hesitancy in this region [18, 19] . However, the Southern states such as Virginia, Tennessee, North Carolina, and South Carolina had among the highest completion rates in the country, yet compliance rates were moderate. This indicates that children were receiving vaccines late, but catching up with the required number of doses by 24 months. Such a trend may suggest issues with access to vaccines or missed opportunities to vaccinate. In addition, vaccine shortages due to increased demand, delays in manufacturing or shipping, new indications, discontinued products, or cold-chain disruption can lead to delayed and incomplete vaccination. At the time of this study, the authors did not find evidence of national vaccine shortages; however, unobserved shortages at the local level may have impacted geographic differences in vaccine completion and compliance.
The NIS has several limitations. The telephone survey methodology relies on the household respondent to identify all vaccine providers and for these providers to accurately report vaccination history. There is potential bias due to households without landline or cell phone service and nonresponse. It is also possible some providers were not identified or that those who were identified did not report the child's entire vaccine history. This could result in some children being misclassified in our study with regard to completion and compliance measures. In addition, the NIS lacks assessment of knowledge, attitudes, beliefs, or other factors related to vaccination that could provide a better understanding of reasons for undervaccination. Although the NIS sample is weighted to represent the national population, sample sizes within each state are small and result in wide confidence intervals. Other data sources, such as vaccine surveillance data captured in state or regional Immunization Information Systems (IIS), include population-level data for a given geographic region and may be utilized to examine local vaccine completion and compliance with a more precise estimate for a specific geographic region or population. Future studies may consider validating NIS estimates with IIS data or other population-based data sources.
Conclusions
Despite these limitations, the NIS is a unique, publically available dataset that tracks childhood vaccinations at the state and national level; therefore, it is an important source for measuring vaccination completion and compliance. Our study evaluates a recent cycle of the NIS, adding to the literature on estimating vaccination trends. Our findings indicated that although completion rates were relatively high, a large proportion of children remained undervaccinated for some period before age 2 years, leaving them at risk during a vulnerable period in life. Although vaccine compliance rates improved over the past decade, rates remain low, as only a quarter of children received all age-appropriate vaccinations. As the recommended vaccine schedule is built on evidence of vaccine effectiveness and synchronization with the standard well-child visit schedule, the lack of vaccine compliance may signify underutilization of other preventative care (e.g., developmental milestone assessments). Future research quantifying the impact of missed well-child visits, opportunities for vaccination, and other preventative health interventions should be explored. Use of automated clinical decision support tools, vaccine forecasters, and reminderrecall systems may be integrated into local IIS or medical record systems as they are effective, evidence-based methods for increasing vaccination rates [20] . Programs such as home nurse visits, the Vaccines for Children program, local school and childcare immunization policy, and integration of vaccine forecasting in alternative settings (e.g., Women, Infant, and Children programs) enhancing access to vaccines, which may result in improved vaccination rates. Sustained efforts involving educational, clinical, and policy interventions should continue to reach optimum vaccination levels as recommended by the ACIP.
Trademark statements
Rotarix TM is a trademark of the GSK group of companies. RotaTeq is a trademark of Merck & Co., Inc.
Role of the funding source
GlaxoSmithKline Biologicals SA funded this research (GSK study number: HO-14-14321) and was involved together with RTI Health Solutions in all stages of study conduct, including management, analysis of the data and interpretation of the data. GlaxoSmithKline Biologicals SA also took in charge all costs associated with the development and publication of this manuscript.
